RT @_TanyaBondar_: Therapies hitting multiple targets at once leave a pathogen or a cancer cell less chance to escape. That's why multi-pro…
RT @MichaelodwyerMD: Congratulations @fdezdelarrea Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting…
RT @Transplant_Doc: Dual-Targeted CAR T-cell Therapy Simultaneously Targeting #BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Mu…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @ESmithMDPhD: Out in @BCD_AACR! Congrats @fdezdelarrea and all our collaborators for impressive work investigating dual-targeted CAR T c…
RT @BCD_AACR: Just published #OnlineFirst! Defining an optimal dual-targeted #CARTcelltherapy approach simultaneously targeting BCMA and GP…
Congratulations Carlos @fdezdelarrea!!! 👏🏻👏🏻 great job!!!!
RT @ESmithMDPhD: Out in @BCD_AACR! Congrats @fdezdelarrea and all our collaborators for impressive work investigating dual-targeted CAR T c…
RT @Transplant_Doc: Dual-Targeted CAR T-cell Therapy Simultaneously Targeting #BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Mu…
RT @ESmithMDPhD: Out in @BCD_AACR! Congrats @fdezdelarrea and all our collaborators for impressive work investigating dual-targeted CAR T c…
RT @ESmithMDPhD: Out in @BCD_AACR! Congrats @fdezdelarrea and all our collaborators for impressive work investigating dual-targeted CAR T c…
RT @Transplant_Doc: Dual-Targeted CAR T-cell Therapy Simultaneously Targeting #BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Mu…
RT @Transplant_Doc: Dual-Targeted CAR T-cell Therapy Simultaneously Targeting #BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Mu…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @Transplant_Doc: Dual-Targeted CAR T-cell Therapy Simultaneously Targeting #BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Mu…
Hoping for more durable responses #Myeloma with these novel approaches
RT @LUMICKS_nl: In this study, the z-Movi® helped to distinguish myeloma cell binding efficacy between #CART cells through in vivo-correlat…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @MichaelodwyerMD: Congratulations @fdezdelarrea Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting…
RT @BCD_AACR: Just published #OnlineFirst! Defining an optimal dual-targeted #CARTcelltherapy approach simultaneously targeting BCMA and GP…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @BCD_AACR: Just published #OnlineFirst! Defining an optimal dual-targeted #CARTcelltherapy approach simultaneously targeting BCMA and GP…
RT @BCD_AACR: Just published #OnlineFirst! Defining an optimal dual-targeted #CARTcelltherapy approach simultaneously targeting BCMA and GP…
Now #OnlineFirst! @BCD_AACR | @ESmithMDPhD @LabWendel @BrentjensRenier & colleagues @sloan_kettering | Define dual-targeted #CARTcelltherapy approach targeting BCMA & GPRC5D to prevent BCMA escape– driven relapse in #MultipleMyeloma #mmsm #hemeon
RT @LUMICKS_nl: In this study, the z-Movi® helped to distinguish myeloma cell binding efficacy between #CART cells through in vivo-correlat…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
Enhorabuena!!
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma https://t.co/MwMY1LgbDH
RT @_TanyaBondar_: Therapies hitting multiple targets at once leave a pathogen or a cancer cell less chance to escape. That's why multi-pro…
Keeping an eye on these dual-targeted approaches🧐https://t.co/9vxLoAZzlq
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @_TanyaBondar_: Therapies hitting multiple targets at once leave a pathogen or a cancer cell less chance to escape. That's why multi-pro…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @MichaelodwyerMD: Congratulations @fdezdelarrea Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @ESmithMDPhD: Out in @BCD_AACR! Congrats @fdezdelarrea and all our collaborators for impressive work investigating dual-targeted CAR T c…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @CTCTC_tmc: #Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in…
#Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in #Multiple Myeloma https://t.co/FZhU2sL0sO @DrGauravNarula @bagalbp @AlbeenaDr
RT @Kwudhikarn: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Esca…
Congratulations Carlos!!👏👏
In this study, the z-Movi® helped to distinguish myeloma cell binding efficacy between #CART cells through in vivo-correlating avidity measurements. Learn more about CART analysis through avidity in our #webinar! Register now➡️https://t.co/pa8wn4NzFd h
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @ESmithMDPhD: Out in @BCD_AACR! Congrats @fdezdelarrea and all our collaborators for impressive work investigating dual-targeted CAR T c…
Out in @BCD_AACR! Congrats @fdezdelarrea and all our collaborators for impressive work investigating dual-targeted CAR T cell therapy approaches. Important lessons for how dual-targeted CAR design impacts function in settings of varying antigen expression.
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
@ESmithMDPhD
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @sloan_kettering Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D https://t.co/Jmm
RT @MichaelodwyerMD: Congratulations @fdezdelarrea Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting…
RT @Abdallah81MD: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Es…
RT @MichaelodwyerMD: Congratulations @fdezdelarrea Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting…
RT @AuclairDan: Defining an Optimal Dual-Targeted #CART -cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Esc…
RT @RogierReijmers: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA…
Congratulations @fdezdelarrea Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma | Blood Cancer Discovery #mmsm #CART https://t.co/TZyQzUW5YR
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma https://t.co/fbeollBJjW FIrst data published with our z-Movi cell avidity analyzer @LUMICKS_nl
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma | Blood Cancer Discovery https://t.co/CUyHEn8gmA
RT @AuclairDan: Defining an Optimal Dual-Targeted #CART -cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Esc…
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma #mmsm https://t.co/lCg0BHFzty
"A bicistronic vector encoding two CARs avoids the challenge of parallel manufacturing separate CAR T-cell products, while providing superior efficacy; this dual-targeted approach may enhance the durability of responses to cellular therapy for myeloma." @E
Defining an Optimal Dual-Targeted #CART -cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple #Myeloma #mmsm @ESmithMDPhD https://t.co/KVVONksb67
RT @BCD_AACR: Just published #OnlineFirst! Defining an optimal dual-targeted #CARTcelltherapy approach simultaneously targeting BCMA and GP…
Therapies hitting multiple targets at once leave a pathogen or a cancer cell less chance to escape. That's why multi-pronged CAR T cells are promising. One can think of them as a living combo drug. Check out this new study targeting two #MultipleMyeloma a
Just published #OnlineFirst! Defining an optimal dual-targeted #CARTcelltherapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape– driven relapse in #MultipleMyeloma. @sloan_kettering #mmsm #hemeonc https://t.co/I9IBHJtT9b https://t.